Sinovac PCV13

BIOLOGICAL3 trials

Sponsors

Sinovac Research and Development Co., Ltd., Sinovac Life Sciences Co., Ltd.

Conditions

Pneumococcal Infectious DiseasePneumococcal Infectious Diseases

Phase 1

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

CompletedNCT06183216

Sinovac Research and Development Co., Ltd.Pneumococcal Infectious Disease

Start: 2024-01-04End: 2025-03-26Updated: 2026-01-28

Phase 3

Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

RecruitingNCT06617715

Sinovac Life Sciences Co., Ltd.Pneumococcal Infectious Disease

Start: 2024-10-23End: 2026-07-30Target: 3080Updated: 2026-01-28

Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)

Not yet recruitingNCT07593924

Sinovac Life Sciences Co., Ltd.Pneumococcal Infectious Diseases

Start: 2026-05-01End: 2027-07-01Target: 500Updated: 2026-05-18